CA
NZ
UK
AU
IND
US
In light of this substantial divestiture, investors will want to consider how Edgewise plans to translate financial security into growth.
Such movement reveals a marked confidence in Bio-Techne's strategic positioning compared to its peers. With market capitalization now at $11.22 billion, investors are taking note of its resilience. Realizing gains like this amid underperforming competitors adds a layer of interest for market participants observing …
BioVie Inc. (NASDAQ: BIVI) announced favorable results from its Phase 2 SUNRISE-PD trial of bezisterim, demonstrating significant improvements in early-stage Parkinson's disease patients. The trial's primary focus was to assess the drug’s impact on motor and non-motor symptoms, with topline results showing that bezisterim …
CareCloud, Inc. (NASDAQ: CCLD) reported a significant revenue increase of 16% to $31.9 million for the quarter ended June 30, continuing its pattern of positive growth. This performance aligns with industry expectations, as the company's earnings per share matched the consensus estimate at $0.06. …
This loss illustrates the ongoing financial commitment the company is making as it progresses its clinical trials aimed at addressing significant unmet needs in autoimmune diseases. The company's shares have risen 23.5% so far this year, but they have faced challenges, dropping 16.9% over …
CG Oncology, Inc. (NASDAQ: CGON) has announced a significant expansion of its stock offering, increasing available shares to be sold by $500 million. This decision comes as the company aims to enhance its financial foundation to support ongoing and future clinical developments. This loss …
Climb Bio, Inc. (NASDAQ: CLYM) unveiled its second-quarter earnings today, revealing an earnings per share (EPS) of $-0.20. This figure exceeds analysts' expectations, who had forecasted a deeper loss of $-0.27. Climb Bio's consistent efforts in executing its clinical trials contribute to its rapid …
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) reported quarterly net revenues of $199.9 million for the period ending June 30, 2026, reflecting a 6% increase from $188 million in the same quarter last year. The company outperformed Wall Street expectations with an adjusted earnings per share …
Compass Therapeutics, Inc. reported a net loss of $25.2 million for the second quarter, which translates to $0.13 per common share. This loss follows an EPS of $-0.10 for the previous quarter, which was in line with analysts' expectations. The disappointing results come as …
The company's market capitalization now stands at approximately $2.4 billion, supporting its value as it approaches potential key moments in research and development. As Amylyx's financials reveal mixed performances, the market remains focused on forthcoming milestones.
Please wait processing your request...